Mr. Smither has served as a member of our Board of Directors since September 2023.
John served as the chief financial officer of Arcutis Biotherapeutics, Inc. from May 2019 to March 2021, and is currently serving as interim chief financial officer, where he was responsible for all financial aspects of Arcutis including leading Arcutis’s successful initial public offering and three follow-on financings. Previously, Mr. Smither was the chief financial officer at Sienna Biopharmaceutics from January 2016 to April 2017, and again from April 2018 to March 2019. Mr. Smither also served as the interim chief financial officer at Kite Pharma, a Gilead Company, from November 2017 through April 2018, and was the chief financial officer of Unity Biotechnology from January 2016 to July 2017. He also served as chief financial officer at Kythera Biopharmaceuticals (“Kythera”), where he was responsible for all financial activities during early clinical stage development through approval and launch, led private fundraising rounds, prepared Kythera for its successful initial public offering in October 2012, and oversaw its acquisition by Allergan plc for approximately $2.1 billion. At Amgen Inc. (“Amgen”), Mr. Smither held several financial positions of increasing responsibility, including vice president of finance and administration for Amgen’s European operations in 28 countries, and served as Executive Director of Corporate Accounting.
In January 2023, Mr. Smither was appointed to the board of NewAmsterdam Pharma and has served as the chair of its audit committee since January 2022. Since January 2022, Mr. Smither has served as a member of the board of directors of Applied Molecular Transport Inc., as chair of its audit committee, and as a member of its compensation committee. Since March 2018, Mr. Smither has served as a member of the board of directors of eFFECTOR Therapeutics Inc. and its predecessor entity, as chair of its audit committee, and as a member of its nominating and corporate governance committee from March 2018 to September 2023. Additionally, from December 2013 to May 2020, Mr. Smither served as a member of the board of directors of Achaogen, Inc., as chair of its audit committee, and as a member of its compensation committee.
Mr. Smither began his career at Ernst & Young, where he was audit partner and held a certification as a Certified Public Accountant (inactive). He holds a B.S. in accounting, with honors, from California State University at Los Angeles.
What is John W. Smither's net worth?
The estimated net worth of John W. Smither is at least $263.24 thousand as of July 1st, 2026. Mr. Smither owns 91,403 shares of Genelux stock worth more than $263,241 as of August 27th. This net worth estimate does not reflect any other assets that Mr. Smither may own. Learn More about John W. Smither's net worth.
How do I contact John W. Smither?
Has John W. Smither been buying or selling shares of Genelux?
During the last quarter, John W. Smither has sold $34,920.00 of Genelux stock. Most recently, John W. Smither sold 12,000 shares of the business's stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $2.91, for a transaction totalling $34,920.00. Following the completion of the sale, the director now directly owns 91,403 shares of the company's stock, valued at $265,982.73. Learn More on John W. Smither's trading history.
Who are Genelux's active insiders?
Are insiders buying or selling shares of Genelux?
In the last year, insiders at the sold shares 15 times. They sold a total of 56,111 shares worth more than $199,950.70. The most recent insider tranaction occured on August, 4th when insider Yong Yu sold 653 shares worth more than $1,919.82. Insiders at Genelux own 7.5% of the company.
Learn More about insider trades at Genelux. Information on this page was last updated on 8/4/2026.
